Compare AFLAC Incorporated (AFL) vs Becton Dickinson and Co (BDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AFLAC Incorporated vs Becton Dickinson and Co — how do they compare? AFLAC Incorporated trades at $120.84 (market cap $60.70B), while Becton Dickinson and Co trades at $180.31 (market cap $49.41B). The key difference: AFLAC Incorporated is the larger of the two by market cap, and Becton Dickinson and Co pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| AFL | BDX | |
|---|---|---|
Market Cap | $60.70B | $49.41B |
Sector | Financials | Health |
52-Week High | $129.55 | $185.39 |
52-Week Low | $103.55 | $138.62 |
Enterprise Value | $70.65B | $65.51B |
Dividend Yield | 2.02% | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFL trades at $121.94, down 2.14% with bearish technical signals and recent earnings misses. The stock shows strong profitability with 26.59% net margin and 16.91% ROE, but faces revenue declines from $19.1B in 2024 to $17.4B in 2025. Recent news highlights AFL's rebranding efforts and dividend consistency amid healthcare cost pressures. Technical indicators show oversold RSI at 17.69 with support at $117.
Outlook remains cautious with mixed analyst sentiment (28% buy, 56% hold) and $118 consensus target below current price. Risks include Japan market exposure and currency headwinds, balanced by 43-year dividend growth history and strong cash flow generation. The stock offers value at 13x P/E but requires monitoring of revenue stabilization.
BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.
The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →
